BioCentury
ARTICLE | Distillery Therapeutics

Hepatic

August 8, 2018 11:48 PM UTC

Mouse studies suggest inhibiting IKKα or its activator MAP3K14 could help treat liver disease. In a partial hepatectomy mouse model of liver injury, hepatocyte-specific knockout of MAP3K14 or IKKα increased hepatocyte proliferation and the ratio of liver weight to body weight compared with normal MAP3K14 or IKKα expression. In mouse models of chemical-induced liver injury and diet-induced non-alcoholic fatty liver disease (NAFLD), hepatocyte-specific knockout of MAP3K14 increased hepatocyte proliferation compared with normal MAP3K14 expression. Next steps could include identifying and testing MAP3K14 and IKKα inhibitors in animal models of liver disease...